Advertisement

Could AstraZeneca's Coronavirus Vaccine Beat Pfizer and Moderna?

Could AstraZeneca's Coronavirus Vaccine Beat Pfizer and Moderna?

Now that AstraZeneca (NASDAQ: AZN) is reporting that its candidate AZD1222 may be 90% effective at preventing coronavirus infections, people all over the world could soon face that choice. If approved vaccines are of equal quality, then choosing the cheaper option is easy. Compared to the candidate produced by Moderna, AZD1222 could be around 5% less effective on the basis of the clinical trial data disclosed so far.